NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

Core Insights - NurExone Biologic Inc. has been accepted into the BioFab Startup Lab, which is part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program, aimed at accelerating the commercialization of regenerative innovations [1][2][3] Company Overview - NurExone is a biotechnology company focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [6] - The company has established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy and plans to create a GMP-compliant facility for naive exosome production [3][6] Industry Context - The BioFab Startup Lab program is federally supported and aims to help early-stage biotechnology companies transition regenerative innovations into scalable manufacturing, reflecting a strategic national capability for the U.S. in biomanufacturing [2][5] - Biofabrication, which involves using living cells and biological materials to manufacture tissues and therapeutic products, is seen as the foundation for next-generation regenerative medicine technologies [4]